Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases

Launched by ASSOCIATION POUR LA RECHERCHE DES THÉRAPEUTIQUES INNOVANTES EN CANCÉROLOGIE · Nov 8, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the addition of a medication called darolutamide to standard treatments for men who have recently been diagnosed with prostate cancer that has spread to the pelvic lymph nodes. The goal is to see if this combination can improve treatment outcomes. The trial is currently looking for men aged 18 and older who have confirmed prostate cancer and specific staging results from imaging scans. To participate, they should not have any cancer spread beyond the pelvic area and should be able to commit to a treatment plan that includes long-term hormone therapy.

Participants in the trial can expect to receive either darolutamide or a placebo (a treatment that looks like darolutamide but has no active ingredients) alongside their regular cancer treatments. The study will involve regular check-ups and monitoring to assess how well the treatment is working and to ensure their health during the trial. It's important for potential participants to know that they must meet certain health criteria and agree to follow study guidelines, including using protection if they are sexually active.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. . Newly diagnosed, histologically confirmed prostate adenocarcinoma
• • 2. ≥ 18 years old.
• • 3. Initial staging with Pelvic MRI, body CT-scan/bone scan or Choline or PSMA PET-CT
• • 4. Any T stage
• • 5. N stage: N1 - Pelvis lymph nodes metastases (upper limit defined as the L4/L5 interspace).
• • 6. Intention to treat with long-term androgen deprivation therapy (24 months).
• • 7. Hormonal therapy with LH-RH agonist or antagonist is allowed up to 3months prior to randomization.
• • 8. Able to receive protocol therapy and have life expectancy of at least 36 months, ECOG Performance Status (PS) 0-2.
• • 9. . Blood counts at screening: hemoglobin ≥ 9.0 g/dl, absolute neutrophil count ≥ 1500/μl (1.5x109/l), platelet count ≥ 100,000/μl (100x109/l ) (patient must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).
• • 10. Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) \< 2.5 x upper limit of normal (ULN), total bilirubin \< 1.5 x ULN (except patients with a diagnosis of Gilbert's disease), creatinine \< 2.0 x ULN.
• • 11. Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method during the study treatment and for 3 months after the end of the study treatment.
• • 12. Written informed consent.
• • 13. Willing and expected to comply with follow-up schedule.
• • 14. Affiliated to the social security system.
• • 15. Use of 5-α reductase inhibitors (finasteride, dutasteride) is allowed
• Exclusion Criteria:
• • 1. Lymph nodes metastases outside of the pelvis
• • 2. Bone or visceral metastases
• • 3. Prior systemic therapy for locally-advanced prostate cancer except for LH-RH agonist or antagonist up to 3 months before randomization
• 4. Prior treatment with:
• • Second generation AR inhibitors such as enzalutamide, apalutamide (ARN-509), darolutamide (ODM-201) other investigational AR inhibitors
• • CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or
• • Oral ketoconazole
• • Use of estrogens, or AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate)
• • 5. Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomization.
• • 6. Patients with QTor QTc interval \> 450 ms on the ECG
• • 7. Initiation of treatment with bisphosphonate or denosumab within 12 weeks before randomization. Patients receiving bone loss prevention treatment on a stable dose of e.g. bisphosphonate or denosumab for at least 28 days before randomization can continue the treatment during the study.
• • 8. Known hypersensitivity to the study treatment (RT, ADT, darolutamide/placebo) or any of its ingredients.
• • 9. Major surgery within 28 days before randomization.
• • 10. Any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV or arterial thromboembolic event.
• • 11. Uncontrolled hypertension as indicated by a resting systolic BP \> 160 mmHg or diastolic BP \> 100 mmHg at screening. Patients may be re-screened after adjustments of anti- hypertensive medications.
• • 12. Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which chemotherapy has been completed \> 5 years ago and from which the patient has been disease-free.
• • 13. Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
• • 14. Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
• • 15. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug
• • 16. Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures.
• • 17. Unable to swallow study medications and comply with study requirements.
• • 18. Galactose intolerance, the Lapp lactase deficiency or glucose galactose-malabsorption
• • 19. History of bilateral hip replacements making IMRT impossible
• • 20. Contra-indications for the administration of any of the study treatments (RT, ADT, Darolutamide/placebo) or any of its ingredients.
• • 21. Patient under guardianship, administrative tutorship and incapable to give informed consent